Irbea Tablets
Irbesartan
150mg
Laboratorios Cinfa S.A
| Pack size | 28's (7's Blister x 4) |
|---|---|
| Dispensing mode | POM |
| Source | SPAIN |
| Agent | Modern Pharmaceutical Co. |
| Retail Price | 39.50 AED |
Available as:
Indications
Irbea Tablets is used for:
Diabetic nephropathy, Hypertension
Adult Dose
Oral
Hypertension
Adult: 150 mg once daily, may increase to 300 mg once daily if needed. Patient w/ intravascular volume depletion: Initially, 75 mg once daily.
Elderly: >75 yr Initially, 75 mg once daily.
Diabetic nephropathy in Type 2 diabetes mellitus
Adult: Initially, 75-150 mg once daily, may increase to 300 mg once daily if needed.
Child Dose
Hypertension
<6 years: Safety and efficacy not established
6-12 years: 75 mg/day PO initially; not to exceed 150 mg/day
>12 years: 150 mg/day PO initially; may be increased to 300 mg/day PO
Renal Dose
Renal impairment:
Haemodialysis: Initially, 75 mg once daily.
Mild-to-severe renal impairment: Dosage adjustment not necessary unless patient is hypovolemic
Administration
May be taken with or without food.
Contra Indications
Hypersensitivity; pregnancy and lactation.
Precautions
Child <6 yr. Unilateral or bilateral renal artery stenosis; vol or Na depletion; aortic or mitral valve stenosis, hypertrophic cardiomyopathy.
Lactation: Potential harm to nursing infant; discontinue drug, or do not nurse
Pregnancy-Lactation
Pregnancy category: 1st trimester, C; 2nd and 3rd trimesters, D
Interactions
May antagonise hypotensive effect and increase risk of nephrotoxicity w/ NSAIDs. May increase serum lithium levels and toxicity. Increased risk of hyperkalaemia w/ K-sparing diuretics (e.g. amiloride, triamterene, spironolactone), K supplements or K-containing salt substitutes.
Potentially Fatal: May increase nephrotoxic, hyperkalaemic and hypotensive effect w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).
Adverse Effects
Side effects of Irbesartan :
>10%
Hyperkalemia (19%)
1-10%
Dizziness (10%), Upper respiratory tract infection (URTI) (9%), Orthostatic hypotension (5%), Fatigue (4%), Diarrhea (3%), Dyspepsia (2%)
Mechanism of Action
Irbesartan is an angiotensin II receptor antagonist. It blocks the vasoconstricting and aldosterone-secreting effects of angiotensin II by binding to AT1 receptors.
Note
Irbea 150mg Tablets manufactured by Laboratorios Cinfa S.A. Its generic name is Irbesartan. Irbea is availble in United Arab Emirates.
Farmaco UAE drug index information on Irbea Tablets is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.
Some other brands of Irbesartan :
Tablets / Film-coated
Gizlan
150mg
Dar Al Dawa Development & Investment Co. Ltd.
Tablets / Film-coated
Gizlan
300mg
Dar Al Dawa Development & Investment Co. Ltd.
Tablets
Irbea
300mg
Laboratorios Cinfa S.A
Tablets
Irbea
75mg
Laboratorios Cinfa S.A
Tablets / Film-coated
Irbemac
150mg
Macleods Pharmaceuticals Ltd.